Tag Archive for: sino biological

Sino Biological

Nanobodies: An Important Tool for the Next Generation of Tumor Diagnostics and Therapeutics

Nanobodies are emerging as important tools for tumor diagnosis and treatment due to their small size, simple humanization, low immunogenicity, superior affinity and stability, high penetration, and adequate levels of solubility, and are expected to revolutionize the antibody-based drug therapy. In 2018, the world´s first nanobody was approved for marketing in the European Union to treat adult patients with acquired thrombotic thrombocytopenic purpura. At present, more than 20 nanobodies are being tested in clinical research worldwide, mostly in clinical phase I or II.

Read more
Sino Biological

Anti-ID antibody production

An anti-idiotypic anti­body (anti-ID Ab) can recognise and bind to the idiotypic center of another antibody. Anti-idiotype antibodies are widely used in therapeutic drug development, such as immunogenicity assessments, pharmacokinetic/pharmacodynamics (PK/PD) studies, and vaccine development.

Read more
Sino Biological

Sino Biological and Ainnocence Partner to Offer Next-Generation Antibody Development CRO Services

Sino Biological, a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047), which provides biological research reagents and related technical is pleased to announce a CRO services partnership with Ainnocence, Inc. of San Jose, California.

Read more
Sino Biological

Recombinant production

Sino Biological specializes in recombinant production of antibodies and proteins. The company routinely conducts high-throughput projects of up to 1,000 per batch. Sino Biological’s manufacturing facility can also handle large-scale production at gram level.

Read more
Sino Biological

Sino Biological Establishes New Location in Houston, Texas

Sino Biological, Inc., a biotechnology company listed on ChiNext (SZSE: 301047), provides biological research reagents and related technical contract research services, is pleased to announce its physical geographic expansion, adding a new location in Houston, Texas.

Read more
Sino Biological

Sino Biological Deposits Recombinant Omicron Proteins and Antibodies to BEI Resources

Sino Biological, Inc. has recently deposited reagents for the Omicron variant, including recombinant proteins to Spike and Nucleocapsid, and antibody products to a central repository for reagents to support infectious disease research. With the addition of the Omicron products to previously deposited array of SARS-CoV-2 reagents, researchers can readily get access to them by registering with BEI Resources.

Read more
Sino Biological

Sino Biological Newly Launched A Panel of Research Reagents for SARS-CoV-2 Omicron Variant (B.1.1.529)

Sino Biological, Inc. announced today that it has launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-CoV-2 virus, which quickly raised concerns around the world because of the high number of mutations it carries, especially the 30-plus mutations on the Spike protein.

Read more
Sino Biological

Sino Biological, Inc. to be Featured on Worldwide Business with kathy ireland®

Sino Biological, a biotechnology company which provides biological research reagents and related technical contract research services, will be featured on Worldwide Business with kathy ireland, airing on FOX Business Network, Bloomberg International and other outlets as sponsored content. Hosted by business mogul Kathy Ireland, this award-winning television series takes an in-depth look at companies around the world currently impacting different sectors of business and society. Dr. Rob Burgess, Chief Business Officer for Sino Biological, will be interviewed.

Read more
Sino Biological

Study COVID-19 variants

Three fast-spreading new variants of SARS-CoV-2 virus have emerged in recent months: the U.K. variant B.1.1.7, the Brazil variant P.1, and the South Africa variant B.1.351.

Read more